Study to Assess the Pharmacokinetics, Safety and Tolerability of Aztreonam-Avibactam in Healthy Chinese Participants.

A PHASE I, SINGLE CENTER, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM ADMINISTERED AS SINGLE AND REPEATED INTRAVENOUS DOSES IN HEALTHY CHINESE PARTICIPANTS

A Phase 1, single center, single arm, open-label study to assess the PK, safety and tolerability of Aztreonam-Avibactam after single and repeated IV infusion of doses in healthy Chinese participants.

Inclusion Criteria:

• Healthy Chinese male and female participants
• No clinical relevant abnormalities
• willing and able to comply with all study procedures
• BMI:17.5-30.5
• Sign informed consent

Exclusion Criteria:

• Any clinical significant illness
• History of alcohol abuse
• Use within 14 days prior the first study dose
• CL>80ml/min
• Abnormal vital signs, such 12-ECG, blood pressure and pulse rate
• Blood donation within 60days
• History of HIV, HBsAg, HBcAb, HCVAb
• Other medical or psychiatric may inappropriate for the study